gem-Dimethyl-bearing C-Glucosides as Sodium-glucose Co-transporter 2 （SGLT2） Inhibitors

Three novel gem-dimethyl C-glucosides were designed as sodium-glucose co-transporter 2 （SGLT2） inhibitors, and their syntheses started from D-glucose and three 2-substituted-5-bromobenzoic acids were achieved via a facile 8-step protocol, with the key step being anhydrous aluminum chloride-catalyzed...

Full description

Saved in:
Bibliographic Details
Published in中国化学：英文版 Vol. 29; no. 6; pp. 1192 - 1198
Main Author Shi, Yongheng Zhao, Guilong Lou, Yuanyuan Wang, Yuli Shao, Hua Liu, Wei Xu, Weiren Tang, Lida
Format Journal Article
LanguageEnglish
Published 2011
Subjects
二甲基
协议实现
宝石
抑制剂
苷
葡萄糖转运
轴承
钠
Online AccessGet full text

Cover

More Information
Summary:Three novel gem-dimethyl C-glucosides were designed as sodium-glucose co-transporter 2 （SGLT2） inhibitors, and their syntheses started from D-glucose and three 2-substituted-5-bromobenzoic acids were achieved via a facile 8-step protocol, with the key step being anhydrous aluminum chloride-catalyzed Friedel-Crafts alkylation of tertiary alcohols and phenetol. These three SGLT2 inhibitors were evaluated in vivo with a mice oral glucose tolerance test （OGTT）, and the anti-hyperglycemic activities of all these three compounds were comparable with that of the positive control Dapagliflozin.
Bibliography:sodium-glucose co-transporter 2 （SGLT2）, gem-dimethyl, synthesis, Friedel-Crafts alkylation, oral glucose tolerance test （OGTT）
31-1547/O6
Three novel gem-dimethyl C-glucosides were designed as sodium-glucose co-transporter 2 （SGLT2） inhibitors, and their syntheses started from D-glucose and three 2-substituted-5-bromobenzoic acids were achieved via a facile 8-step protocol, with the key step being anhydrous aluminum chloride-catalyzed Friedel-Crafts alkylation of tertiary alcohols and phenetol. These three SGLT2 inhibitors were evaluated in vivo with a mice oral glucose tolerance test （OGTT）, and the anti-hyperglycemic activities of all these three compounds were comparable with that of the positive control Dapagliflozin.
ISSN:1001-604X
1614-7065